VEGF/VEGFR2 interaction down-regulates matrix metalloproteinase-9 via STAT1 activation and inhibits B chronic lymphocytic leukemia cell migration.

No abstract is available for this paper.

• Publication year

  2010

• Venue

  Blood

• Publication date

  2010-01-28

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1182/blood-2009-08-239426PMID 19965686
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• VEGF receptors on chronic lymphocytic leukemia (CLL) B cells interact with STAT 1 and 3: implication for apoptosis resistance

  2010cited by this paper
• Measurement of Phosphorylated Extracellular Signal–Regulated Kinase 1 and 2 in an Undergraduate Teaching Laboratory with ALPHAscreen Technology

  2009cited by this paper
• TRPM2 Functions as a Lysosomal Ca2+-Release Channel in β Cells

  2009cited by this paper
• Positive and Negative Modulation of Angiogenesis by VEGFR1 Ligands

  2009cited by this paper
• Proteomic Analysis of Integrin-Associated Complexes Identifies RCC2 as a Dual Regulator of Rac1 and Arf6

  2009cited by this paper
• Alpha4beta1 integrin and 190-kDa CD44v constitute a cell surface docking complex for gelatinase B/MMP-9 in chronic leukemic but not in normal B cells.

  2008cited by this paper
• Matrix metalloproteinase-9 is up-regulated by CCL21/CCR7 interaction via extracellular signal-regulated kinase-1/2 signaling and is involved in CCL21-driven B-cell chronic lymphocytic leukemia cell invasion and migration.

  2008cited by this paper
• Pathophysiologic mechanisms of chronic lymphocytic leukemia and their application to therapy.

  2007cited by this paper
• MMP-9 in B-cell chronic lymphocytic leukemia is up-regulated by alpha4beta1 integrin or CXCR4 engagement via distinct signaling pathways, localizes to podosomes, and is involved in cell invasion and migration.

  2006cited by this paper
• VEGF receptor signalling ? in control of vascular function

  2006cited by this paper
• Interferon-gamma-activated STAT-1alpha suppresses MMP-9 gene transcription by sequestration of the coactivators CBP/p300.

  2005cited by this paper
• Autocrine VEGF mediates the antiapoptotic effect of CD154 on CLL cells

  2005cited by this paper
• The vascular endothelial growth factor (VEGF)/VEGF receptor system and its role under physiological and pathological conditions.

  2005cited by this paper
• Interferon‐γ‐activated STAT‐1α suppresses MMP‐9 gene transcription by sequestration of the coactivators CBP/p300

  2005cited by this paper
• VEGF receptors on chronic lymphocytic leukemia (CLL) B cells interact with STAT 1 and 3: implication for apoptosis resistance

  2005cited by this paper
• CLL, but not normal, B cells are dependent on autocrine VEGF and alpha4beta1 integrin for chemokine-induced motility on and through endothelium.

  2005cited by this paper
• Inhibition of matrix metalloproteinase‐9 by interferons and TGF‐β1 through distinct signalings accounts for reduced monocyte invasiveness

  2005cited by this paper
• The role of matrix metalloproteinase  9 in the pathogenesis of chronic lymphocytic leukaemia

  2004cited by this paper
• Advances in the understanding of biology and prognosis in chronic lymphocytic leukemia

  2004cited by this paper
• Placenta growth factor-1 antagonizes VEGF-induced angiogenesis and tumor growth by the formation of functionally inactive PlGF-1/VEGF heterodimers.

  2002cited by this paper
• Production of matrix metalloproteinase-9 in early stage B-CLL: suppression by interferons

  2002cited by this paper
• Transcriptional suppression of matrix metalloproteinase-9 gene expression by IFN-gamma and IFN-beta: critical role of STAT-1alpha.

  2001cited by this paper
• Transcriptional Suppression of Matrix Metalloproteinase-9 Gene Expression by IFN-γ and IFN-β: Critical Role of STAT-1α1

  2001cited by this paper
• In vitro and in vivo production of vascular endothelial growth factor by chronic lymphocytic leukemia cells.

  2000cited by this paper
• Increased bone marrow angiogenesis in B cell chronic lymphocytic leukemia

  2000cited by this paper
• Clinical relevance of intracellular vascular endothelial growth factor levels in B-cell chronic lymphocytic leukemia.

  2000cited by this paper
• Vascular Endothelial Growth Factor Activates STAT Proteins in Aortic Endothelial Cells*

  2000cited by this paper
• Synthesis and biological evaluations of 3-substituted indolin-2-ones: a novel class of tyrosine kinase inhibitors that exhibit selectivity toward particular receptor tyrosine kinases.

  1998cited by this paper

• Tumor Cell Survival Factors and Angiogenesis in Chronic Lymphocytic Leukemia: How Hot Is the Link?

  2024cites this paper
• CD38/NAD+ glycohydrolase and associated antigens in chronic lymphocytic leukaemia: from interconnected signalling pathways to therapeutic strategies.

  2024cites this paper
• Synthesis, biological assessment, and in silico binding mode interaction analyses and DFT studies of biphenylsulfonamide-based potent MMP-2 inhibitors effective against chronic myeloid leukemia

  2024cites this paper
• Anti-angiogenic effects of aqueous extract from Agrostemma githago L. seed in human umbilical vein endothelial cells via regulating Notch/VEGF, MMP2/9, ANG2, and VEGFR2

  2022cites this paper
• Regulation and function of angiogenic factors in chronic lymphocytic leukemia

  2021cites this paper
• Inhibitors of gelatinases (MMP-2 and MMP-9) for the management of hematological malignancies.

  2021cites this paper
• Metalloproteinases in Ovarian Cancer

  2021cites this paper
• Research on Active Compounds of Huanglian Jiedu Decoction for the Treatment of Corona Virus Disease 2019 Based on Network Pharmacology and Molecular Docking

  2020cites this paper
• Minimal spatial heterogeneity in chronic lymphocytic leukemia at diagnosis

  2020cites this paper
• Anti-VEGF Drugs in the Treatment of Multiple Myeloma Patients

  2020cites this paper
• Vascular endothelial growth factor gene polymorphism in Egyptian patients with B-cell chronic lymphocytic leukemia

  2020cites this paper
• Endothelial dysfunction in patients with lymphoproliferative disorders and its changes in the course of polychemotherapy

  2020cites this paper
• Matrix metalloproteinase-9 induces a pro-angiogenic profile in chronic lymphocytic leukemia cells.

  2019cites this paper
• Biomarkers of cavernous angioma with symptomatic hemorrhage.

  2019cites this paper
• Angiotensin 1–7 modulates molecular and cellular processes central to the pathogenesis of prostate cancer

  2018cites this paper
• Liposome‐Encapsulated Hemoglobin Accelerates Skin Wound Healing in Diabetic dB/dB Mice

  2017influential citation
• Overexpression of Hiwi Inhibits the Growth and Migration of Chronic Myeloid Leukemia Cells

  2015cites this paper
• Tumor angiogenesis: MMP-mediated induction of intravasation- and metastasis-sustaining neovasculature.

  2015cites this paper
• VEGF-mediated suppression of cell proliferation and invasion by miR-410 in osteosarcoma

  2015cites this paper
• RIG-I suppresses the migration and invasion of hepatocellular carcinoma cells by regulating MMP9.

  2015cites this paper
• Vascular Endothelial Growth Factor A (VEGFA) Gene Polymorphisms Have an Impact on Survival in a Subgroup of Indolent Patients with Chronic Lymphocytic Leukemia

  2014cites this paper
• A murine–human chimeric IgG antibody against vascular endothelial growth factor receptor 2 inhibits angiogenesis in vitro

  2014cites this paper
• Dual VEGF/VEGFR inhibition in advanced solid malignancies

  2014cites this paper
• Mechanisms of action of the anti-VEGF monoclonal antibody bevacizumab on chronic lymphocytic leukemia cells.

  2013cites this paper
• Critical signal transduction pathways in CLL.

  2013cites this paper
• primary co-cultures by altering the myeloid microenvironment Lenalidomide reduces survival of chronic lymphocytic leukemia cells in

  2013cites this paper
• STAT1 and STAT3 in tumorigenesis

  2012cites this paper
• Angiogenic factors in chronic lymphocytic leukemia.

  2012cites this paper
• Targeting the vascular endothelial growth factor in hematologic malignancies

  2012cites this paper
• Role of VEGF/VEGFR in the pathogenesis of leukemias and as treatment targets (Review).

  2012cites this paper
• Lenalidomide reduces survival of chronic lymphocytic leukemia cells in primary cocultures by altering the myeloid microenvironment.

  2012cites this paper
• The Mechanisms of Cerebral Vascular Dysfunction and Neuroinflammation by MMP-Mediated Degradation of VEGFR-2 in Alcohol Ingestion

  2012cites this paper
• Astrocyte TLR4 activation induces a proinflammatory environment through the interplay between MyD88‐dependent NFκB signaling, MAPK, and Jak1/Stat1 pathways

  2011cites this paper
• REGULACIÓN Y FUNCIÓN DE LA METALOPROTEINASA DE MATRIZ (MMP-9) EN LA LEUCEMIA LINFOCÍTICA CRÓNICA-B Y SU PAPEL EN LA PATOGÉNESIS DE LA ENFERMEDAD.

  2010cites this paper
• Matrix metalloproteinases.

  2010cites this paper
• Phase II trials of single-agent anti-VEGF therapy for patients with chronic lymphocytic leukemia

  2010cites this paper
• Megakaryocytes join the war on cancer.

  2010cites this paper
• Riding the 2-edged sword.

  2010cites this paper
• STAT1 and STAT3 in tumorigenesis: A matter of balance

  year unknowncites this paper